Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review

Fundamental and Clinical Pharmacology

Volumn 20, Issue 6, 2006, Pages 563-576

  Idée, Jean Marc ^a   Port, Marc ^a   Raynal, Isabelle ^a   Schaefer, Michel ^a   Le Greneur, Soizic ^a   Corot, Claire ^a  

^a Research Division   (France)

Author keywords

Analytical interference; Contrast agents; Gadolinium; Magnetic resonance imaging; Spurious hypocalcaemia; Transmetallation

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; COPPER; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GALLIUM 67; ZINC;

CALCIUM BLOOD LEVEL; CHELATION; CHEMICAL STRUCTURE; COLORIMETRY; CONTRAST ENHANCEMENT; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; METALLATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; THERMODYNAMICS;

BIOLOGICAL MARKERS; CALCIUM; CATIONS; COLORIMETRY; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; ORGANOMETALLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TISSUE DISTRIBUTION;

EID: 33751067666     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00447.x     Document Type: Review

References (74)

1. Muroff L.R. MRI contrast: current agents and issues. Appl. Radiol. (2001) 30 (Suppl.) 5-7.
2. Guerbet Annual Report. (2005) http://new.guerbet-group. com/fileadmin/user_upload/investors/reports/2005/lang_en/Guerbet_2005_Annual- Report.pdf [accessed on 2 November 2006].
3. Caravan P., Ellison J., McMurry T.J., Lauffer R.B. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics and applications. Chem. Rev. (1999) 99 2293-2352.
4. Bellin M.F., Vasile M., Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur. Radiol. (2003) 13 2688-2698.
5. Le Mignon M.M., Chambon C., Warrington S., Davies R., Bonnemain B. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest. Radiol. (1990) 25 933-937.
6. Staks T., Schuhmann-Giampieri G., Frenzel T., Weinmann H.J., Lange L., Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest. Radiol. (1994) 29 709-715.
7. Tombach B., Bremer C., Reimer P. et al. Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest. Radiol. (2000) 35 35-40.
8. Townsend R.R., Cohen D.L., Katholy R. et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am. J. Kidney Dis. (2000) 36 1207-1212.
9. Joffe P., Thomsen H.S., Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad. Radiol. (1998) 5 491-502.
10. Kirchin M.A., Runge V.M. Contrast agents for magnetic resonance imaging. Top. Magn. Reson. Imaging (2003) 14 426-435.
11. Murphy K.J., Brunberg J.A., Cohan R.H. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am. J. Roentgenol. (1996) 167 847-849.
12. Lorusso V., Pascolo L., Fernetti C., Anelli P.L., Uggeri F., Tiribelli C. Magnetic resonance contrast agents: from the bench to the patient. Curr. Pharm. Des. (2005) 11 4079-4098.
13. Rohrer M., Bauer H., Mintorovitch J., Requard M., Weinmann H.J. Comparison of magnetic properties of MRI contrast media solutions at different field strengths. Invest. Radiol. (2005) 40 715-724.
14. Lansman J.B. Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J. Gen. Physiol. (1990) 95 679-696.
15. Biagi B.A., Enyeart J.J. Gadolinium blocks low- and highthreshold calcium currents in pituitary cells. Am. J. Physiol. (1990) 259 C515-C520.
16. Evans C.H. Biochemistry of the lanthanides, Plenum Press, New York, 1990.
17. 2+-adenosine triphosphatase of sarcoplasmic reticulum. J. Biochem. (Tokyo) (1984) 95 661-669.
18. Husztik E., Lazar G., Parducz A. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br. J. Exp. Pathol. (1980) 61 624-630.
19. Palasz A., Czekaj P. Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim. Pol. (2000) 47 1107-1114.
20. Bousquet J.C., Saini S., Stark D.D. et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology (1988) 166 693-698.
21. Nordenbo A.M., Somnier F.E. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Lancet (1992) 340 1168.
22. Kumar K. Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents. J. Alloys Compd. (1997) 249 163-172.
23. Cacheris W.P., Quay S.C., Rocklage S.M. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn. Reson. Med. (1990) 8 467-481.
24. Tweedle M.F. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest. Radiol. (1992) 27 (Suppl. 1) S2-S6.
25. Tweedle M.F., Hagan J.J., Kumar K., Mantha S., Chang C.A. Reaction of gadolinium chelates with endogenously available ions. Magn. Reson. Imaging (1991) 9 409-415.
26. Okazaki O., Kurata T., Yoshioka N., Hakusui H. Pharmacokinetics and stability of caldiamide sodium in rats. Arzneimittelforschung (1996) 46 79-83.
27. Laurent S., Vander Elst L., Copoix F., Muller R.N. Stability of MRI paramagnetic contrast media. A proton relaxometric protocol for transmetallation assessment. Invest. Radiol. (2001) 36 115-122.
28. n in mice. Nucl. Med. Biol. (1988) 15 395-402.
29. Tweedle M.F., Wedeking P., Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest. Radiol. (1995) 30 372-380.
30. Wedeking P., Kumar K., Tweedle M.F. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn. Reson. Imaging (1992) 10 641-648.
31. Gibby W.A., Gibby K.A., Gibby W.A. Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest. Radiol. (2004) 39 138-142.
32. White G.W., Gibby W.A., Tweedle M.F. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest. Radiol. (2006) 41 272-278.
33. 3+ ions. Contrast Med. Mol. Imaging (2006) 1 23-29.
34. McCall K.A., Huang C.C., Fierke C.A. Function and mechanism of zinc metalloenzymes. J. Nutr. (2000) 130 1437S-1446S.
35. Turner A.J. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem. Soc. Trans. (2003) 31 723-727.
36. Sturrock E.D., Natesh R., Van Rooyen J.M., Acharya K.R. Structure of angiotensin-1 converting enzyme. Cell. Mol. Life Sci. (2004) 61 2677-2686.
37. Corot C., Idée J.M., Hentsch A.M. et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J. Magn. Reson. Imaging (1998) 8 695-702.
38. Puttagunta N.R., Gibby W.A., Puttagunta V.L. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest. Radiol. (1996) 10 619-624.
39. Puttagunta N.R., Gibby W.A., Smith G.T. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest. Radiol. (1996) 31 739-742.
40. Kimura J., Ishiguchi T., Matsuda J. et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat. Med. (2005) 23 322-326.
41. Mann J.S. Stability of gadolinium complexes in vitro and in vivo. J. Comput. Assist. Tomogr. (1993) 17 (Suppl. 1) S19-S23.
42. Abdou N., Napoli A.M., Hynes M.R., Allen J.C., Wible J.H. Safety assessment of gadoversetamide (OptiMARK) administered by power injector. J. Magn. Reson. Imaging (2004) 19 133-140.
43. Harpur E.S., Worah D., Hals P.A., Holtz E., Furuhama K., Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest. Radiol. (1993) 28 (Suppl. 1) S28-S43.
44. Wible J.H., Troup C.M., Hynes M.R. et al. Toxicological assessment of gadoversetamide injection (OptiMARK®), a new contrast-enhancement agent for use in magnetic resonance imaging. Invest. Radiol. (2001) 36 401-412.
45. Günzel P., Müller N. Toxicology of contrast media for magnetic resonance imaging: a brief review. Adv. MRI Contr. (1992) I (Suppl. 1) 29-36.
46. Mason K.E., Burns W.A., Smith J.C. Testicular damage associated with zinc deficiency in pre- and post-pubertal rats: response to zinc repletion. J. Nutr. (1982) 112 1019-1028.
47. Swenerton H., Hurley L.S. Severe zinc deficiency in male and female rats. J. Nutr. (1968) 95 8-18.
48. Prasad A.S. Clinical manifestations of zinc deficiency. Annu. Rev. Nutr. (1985) 5 341-363.
49. Nodera M., Yanagisawa H., Wada O. Increased apoptosis in a variety of tissues of zinc-deficient rats. Life Sci. (2001) 69 1639-1649.
50. Niendorf H.P., Dinger J.C., Haustein J., Cornelius I., Alhassan A., Clauss W. Tolerance data of Gd-DTPA: a review. Eur. J. Radiol. (1991) 13 15-20.
51. Niendorf H.P., Seifert W. Serum iron and serum bilirubin after administration of Gd-DTPA in healthy volunteers. Invest. Radiol. (1988) 23 (Suppl. 1) S275-S280.
52. Van Wagoner M., O'Toole M., Worah D., Leese P.T., Quay S.C. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest. Radiol. (1991) 26 980-986.
53. Proctor K.A.S., Rao L.V., Roberts W.L. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Am. J. Clin. Pathol. (2004) 121 282-292.
54. Vorobiov M., Basok A., Tovbin D., Shnaider A., Katchko L., Rogachev B. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol. Dial. Transplant. (2003) 18 884-887.
55. Mühler A., Saeed M., Brasch R.C., Higgins C.B. Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium. Radiology (1992) 184 159-164.
56. Idée J.M., Berthommier C., Goulas V. et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals (1998) 11 113-123.
57. Wible J.H., Hynes M.R. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Radiology (2004) 233 158-164.
58. Baker J.F., Kratz L.C., Stevens G.R., Wible J.H. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide (Optimark) in healthy pediatric subjects. Invest. Radiol. (2004) 39 334-339.
59. Löwe A., Balzer T., Hirt U. Interference of gadolinium-containing contrast enhancing agents with colorimetric calcium laboratory testing. Invest. Radiol. (2005) 40 521-525.
60. Prince M.R., Erel H.E., Lent R.W. et al. Gadodiamide administration causes spurious hypocalcemia. Radiology (2003) 227 639-646.
61. Doorenbros C., Ozyilmaz A., Van Wijnen M. Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. N. Engl. J. Med. (2003) 349 817-818.
62. Kefalas C.H., Murray N.G.B., Aguanno J.J. et al. Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis. Liver Transpl. (2004) 10 136-140.
63. Decupere M., Ooms V., Oyen R., Kuypers D.R.J., Claes K. Artifactual hypocalcemia after intravenous administration of gadiodiamide (Omniscan®). Nephrol. Dial. Transplant. (2005) 20 1516-1517.
64. Williams S.F., Meek S.E., Moraghan T.J. Spurious hypocalcemia after gadodiamide administration. Mayo Clin. Proc. (2005) 80 1655-1657.
65. Zhang H.L., Ersoy H., Prince M.R. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements. J. Magn. Reson. Imaging (2006) 23 383-387.
66. Prince M.R., Choyke P.L., Knopp M.V. More on pseudohypocalcemia and gadolinium-enhanced MRI. N. Engl. J. Med. (2004) 350 87-88.
67. Emerson J., Kost G. Spurious hypocalcemia after Omniscanor OptiMARK-enhanced magnetic resonance imaging. Arch. Pathol. Lab. Med. (2004) 128 1151-1156.
68. Normann P.T., Froysa A., Svaland M. interference of gadodiamide injection (Omniscan) on the colorimetric determination of serum calcium. Scand. J. Clin. Lab. Invest. (1995) 55 421-426.
69. Lin J., Idée J.M., Port M. et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J. Pharm. Biomed. Anal. (1999) 21 931-943.
70. Hattner R.S., White D.L. Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. J. Nucl. Med. (1990) 31 1844-1846.
71. Jackson G.E., Byrne M.J. Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. J. Nucl. Med. (1996) 37 379-386.
72. Wiggins J., Goldstein H., Weinmann H. Gallium-67/stable gadolinium antagonism. J. Nucl. Med. (1991) 32 1830-1831.
73. Baker R.J. The effect of gadolinium-based MRI contrast agents on the biodistribution of (67)Ga. Nucl. Med. Commun. (2002) 23 139-145.
74. Marckmann P., Skov L., Rossen K. et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol. (2006) 17 2359-2362.